EU watchdog finds no link of swine flu drug and narcolepsy
Saturday 25 September 2010
The European Medicines Agency said Thursday it had found no link between the Pandemrix swine flu vaccine and the sleeping disorder narcolepsy amid patient concerns, notably in Scandinavia.
The EMA "concluded that the available evidence was insufficient to determine whether there is any link between Pandemrix and reports of narcolepsy, and that further studies were necessary to fully understand this issue", a statement said.
"The ongoing review is complex and will take some three to six months to complete," the London-based body added.
Narcolepsy is a condition in which sufferers suddenly fall into a deep sleep.
Pandemrix - produced by British pharmaceutical company GlaxoSmithKline - has been used since September 2009 for vaccination against H1N1 influenza.
The EMA added on Thursday that it had so far received 81 reports from healthcare professionals suggestive of narcolepsy, including 34 from Sweden, 30 from Finland and 10 from France.
Life & Style blogs
The mother who never gave up on her child abused by the Oxford child sex ring
Britain scrapes into top 25 countries in the world to be a mother in Save the Children report
How to gain confidence and maximise your sexual potential
What do the emoji on Snapchat mean?
The 12 most sexually satisfied countries in the world revealed
- 1 If I were Prime Minister: I'd give tax cuts to the rich, keep Trident, and get my football team wrong
- 2 General Election 2015: 14-year-old boy asks Nick Clegg – 'can you kill Katie Hopkins?'
- 3 University student in court for allegedly covering housemates' food in window cleaner and spit
- 4 Ryan Gosling posts tribute to 'Ryan Gosling Won't Eat His Cereal' creator Ryan McHenry
- 5 Garland shooting: Isis claims attack on Prophet Mohamed cartoon contest in Texas as its first action on US soil
£13676.46 - £16411.61 per annum + OTE: SThree: SThree Trainee Recruitment Cons...
£18000 - £22000 per annum + training: Ashdown Group: Business and Marketing Gr...
£20000 - £25000 per annum + Commission: SThree: Are you great at building rela...
£20000 - £22000 per annum + excellent benefits: Ashdown Group: Application Sup...